Coronary Stenting and Inflammation: Implications for Further Surgical and Medical Treatment

Annals of Thoracic Surgery

Volumn 81, Issue 5, 2006, Pages 1918-1925

  Gomes, Walter J ^a   Buffolo, Enio ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COAGULATING AGENT; CREATINE KINASE; CREATINE KINASE MB; DIPYRIDAMOLE; GLYCERYL TRINITRATE; NITRIC OXIDE; PACLITAXEL; RAPAMYCIN; VASODILATOR AGENT; TROPONIN I;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CORONARY ARTERY ANEURYSM; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DISEASE; CORONARY STENT; CREATINE KINASE BLOOD LEVEL; DISEASE MARKER; DRUG ELUTING STENT; DRUG POTENTIATION; ENDOTHELIUM LESION; ENZYME BLOOD LEVEL; GRAFT PATENCY; HEART MUSCLE INJURY; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RUPTURE; THROMBOCYTE AGGREGATION; THROMBOSIS; TISSUE STRUCTURE; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; CORONARY BLOOD VESSEL; LIPID PEROXIDATION; PATHOLOGY; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR PATENCY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY ARTERY BYPASS; CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; CREATINE KINASE, MB FORM; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; LIPID PEROXIDATION; STENTS; TREATMENT OUTCOME; TROPONIN I; VASCULAR PATENCY;

EID: 33646854877     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2005.10.014     Document Type: Review

References (73)

1. Hofma S.H., Whelan D.M., van Beusekom H.M., et al. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol 32 (1998) 1109-1117
2. Almagor M., Keren A., and Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. Am Heart J 145 (2003) 248-253
3. Aggarwal A., Schneider D.J., Terrien E.F., Terrien Jr. C.M., Sobel B.E., and Dauerman H.L. Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 91 (2003) 1346-1349
4. Gottsauner-Wolf M., Zasmeta G., Hornykewycz S., et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 21 (2000) 1152-1158
5. Gomes W.J., Giannotti-Filho O., Paez R.P., Hossne Jr. N.A., Catani R., and Buffolo E. Coronary artery and myocardial inflammatory reaction induced by intracoronary stent. Ann Thorac Surg 76 (2003) 1528-1532
6. Versaci F., Gaspardone A., Tomai F., Crea F., Chiariello L., and Gioffre P.A. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 85 (2000) 92-95
7. Chew D.P., Bhatt D.L., Robbins M.A., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 104 (2001) 992-997
8. Gaspardone A., Crea F., Versaci F., et al. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol 82 (1998) 515-518
9. Toutouzas K., Colombo A., and Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 25 (2004) 1679-1687
10. Farb A., Kolodgie F.D., Hwang J.Y., et al. Extracellular matrix changes in stented human coronary arteries. Circulation 110 (2004) 940-947
11. Hofma S.H., Whelan D.M., van Beusekom H.M., Verdouw P.D., and van der Giessen W.J. Increasing arterial wall injury after long-term implantation of two types of stent in a porcine coronary model. Eur Heart J 19 (1998) 601-609
12. Danenberg H., Welt F., Walker M., et al. Systemic inflammation induced by lipopolysaccharide increases neointimal formation following balloon and stent injury in rabbits. Circulation 105 (2002) 2917-2922
13. Grewe P.H., Deneke T., Machraoui A., et al. Acute and chronic tissue response to coronary stent implantation. pathologic findings in human specimen. J Am Coll Cardiol 35 (2000) 157-163
14. Versaci F., Gaspardone A., Tomai F., Crea F., Chiariello L., and Gioffre P.A. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 85 (2000) 92-95
15. Liuzzo G., Buffon A., Biasucci L.M., et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 98 (1998) 2370-2376
16. Rajagopal V., Gurm H.S., Bhatt D.L., et al. Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. Am J Cardiol 94 (2004) 190-192
17. Gurm H.S., Bhatt D.L., Lincoff A.M., Tcheng J.E., Kereiakes D.J., and Kleiman N.S. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention. insights from the EPIC, EPILOG, and EPISTENT trials. Heart 89 (2003) 1200-1204
18. Azar R.R., McKay R.G., Kiernan F.J., et al. Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol 80 (1997) 1476-1478
19. Fukuda D., Shimada K., Tanaka A., Kawarabayashi T., Yoshiyama M., and Yoshikawa J. Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 43 (2004) 18-23
20. Hojo Y., Ikeda U., Katsuki T., et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 84 (2000) 83-87
21. Aggarwal A., Schneider D.J., Terrien E.F., Gilbert K.E., and Dauerman H.L. Increase in interleukin-6 in the first hour after coronary stenting. an early marker of the inflammatory response. J Thromb Thrombolysis 15 (2003) 25-31
22. Patti G., Di Sciascio G., D'Ambrosio A., Dicuonzo G., Abbate A., and Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 89 (2002) 372-376
23. Navarro-López F., Francino A., Serra A., et al. Late L-lymphocyte and monocyte activation in coronary restenosis. Evidence for a persistent inflammatory/immune mechanism?. Rev Esp Cardiol 56 (2003) 465-472
24. Bhatt D.L. Inflammation and restenosis. is there a link?. Am Heart J 147 (2004) 945-947
25. Zairis M.N., Ambrose J.A., Manousakis S.J., et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting. the Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 40 (2002) 1375-1382
26. Tsimikas S., Lau H.K., Han K.R., et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and Lp(a). acute and long-term immunological responses to oxidized LDL. Circulation 109 (2004) 3164-3170
27. Schachinger V., Halle M., Minners J., et al. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 30 (1997) 927-934
28. Cutlip D.E., Chhabra A.G., Baim D.S., et al. Beyond restenosis. Five-year clinical outcomes from second-generation coronary stent trials. Circulation 110 (2004) 1226-1230
29. Edelman E.R., and Rogers C. Pathobiologic responses to stenting. Am J Cardiol 81 (1998) 4E-6E
30. Balkwill F., and Mantovani A. Inflammation and cancer. back to Virchow?. Lancet 357 (2001) 539-545
31. Mann D.L. Inflammatory mediators and the failing heart. past, present and foreseeable future. Circ Res 91 (2002) 988-998
32. Behrendt D., and Ganz P. Endothelial function. from vascular biology to clinical applications. Am J Cardiol 90 Suppl (2002) 40L-48L
33. Caramori P.R., Lima V.C., Seidelin P.H., Newton G.E., Parker J.D., and Adelman A.G. Long-term endothelial dysfunction after coronary artery stenting. J Am Coll Cardiol 34 (1999) 1675-1679
34. Janero D.R., and Ewing J.F. Nitric oxide and postangioplasty restenosis. pathological correlates and therapeutic potential. Free Radical Bio Med 29 (2000) 1199-1221
35. Hojo Y., Ikeda U., Katsuki T., et al. Release of endothelin 1 and angiotensin II induced by percutaneous transluminal coronary angioplasty. Catheter Cardiovasc Interv 51 (2000) 42-49
36. Dina J.P., Feres T., Paiva A.C., and Paiva T.B. Role of membrane potential and expression of endothelial factors in restenosis after angioplasty in SHR. Hypertension 43 (2004) 131-135
37. Wykretowicz A., Dziarmaga M., Szczepanik A., Guzik P., and Wysocki H. Prospective evaluation of hydroperoxide plasma levels and stable nitric oxide end products in patients subjected to angioplasty for coronary artery disease. Int J Cardiol 89 (2003) 173-178
38. Inoue K., Abe K., Ando K., et al. Pathological analyses of long-term intracoronary Palmaz-Schatz stenting. Is its efficacy permanent?. Cardiovasc Pathol 13 (2004) 109-113
39. Meuwissen M., van der Wal A.C., de Winter R.J., Koch K.T., Becker A.E., and Piek J.J. Stent inflammation. stent footprint in restenotic tissue retrieved by directional atherectomy. Circulation 106 (2002) 1176-1177
40. Farb A., Weber D.K., Kolodgie F.D., et al. Morphologic predictors of restenosis after coronary stenting in humans. Circulation 105 (2002) 2974-2980
41. Thadani U. Recurrent and refractory angina following revascularization procedures in patients with stable angina pectoris. Cor Artery Dis 15 Suppl 1 (2004) 1-4
42. Lerman A., and Zeiher A.M. Endothelial function. cardiac events. Circulation 111 (2005) 363-368
43. Kamiya H., Ushhijima T., Mukai K., Ikeda C., Ueyama K., and Watanbe G. Late patency of the internal thoracic artery graft in patients with and without previous successful percutaneous transluminal coronary angioplasty. Interactive Cardiovasc Thorac Surg 3 (2004) 110-113
44. Ioannidis J.P., Karvouni E., and Katritsis D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 42 (2003) 1406-1411
45. Ricciardi M.J., Wu E., Davidson C.J., et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 103 (2001) 2780-2783
46. Cantor W.J., Newby L.K., Christenson R.H., et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 39 (2002) 1738-1744
47. Nageh T., Sherwood R.A., Harris B.M., Byrne J.A., and Thomas M.R. Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int J Cardiol 92 (2003) 285-293
48. Selvanayagam J.B., Porto I., Channon K., et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury. insights from cardiovascular magnetic resonance imaging. Circulation 111 (2005) 1027-1032
49. Selvanayagam J.B., Kardos A., Nicolson D., et al. Anteroseptal or apical myocardial infarction. a controversy addressed using delayed enhancement cardiovascular magnetic resonance imaging. J Cardiovasc Magn Reson 6 (2004) 653-661
50. Ricciardi M.J., Davidson C.J., Gubernikoff G., et al. Troponin-I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 145 (2003) 522-528
51. Stone G.W., Webb J., Cox D.A., et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. JAMA 293 (2005) 1063-1072
52. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
53. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., and Fallon J.T. Macrophage infiltration in acute coronary syndromes. implications for plaque rupture. Circulation 90 (1994) 775-778
54. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
55. Kimura T., Abe K., Shizuta S., Odashiro K., Yoshida Y., and Sakai K. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 105 (2002) 2986-2991
56. Gomes W.J., Giannotti-Filho O., Hossne Jr. N.A., Catani R., and Buffolo E. Inflammatory reaction after sirolimus-eluting stent implant. Ann Thorac Surg 80 (2005) 1903-1904
57. Choi S.B. Cypher coronary stents and risk of thrombosis. Can Med Assoc J 169 (2003) 218
58. Babinska A., Markell M.S., Salifu M.O., Akoad M., Ehrlich Y.H., and Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 13 (1998) 3153-3159
59. Tunon M.J., Sanchez-Campos S., Gutierrez B., Culebras J.M., and Gonzalez-Gallego J. Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes. Biochem Pharmacol 66 (2003) 439-445
60. Dibra A., Ndrepepa G., Mehilli J., et al. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. Am J Cardiol 95 (2005) 1238-1240
61. Sardella G, Mariani P, D'Alessandro M, et al. Early elevation of interleukin-1β and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. Thromb Res 2005 [electronic publication ahead of print].
62. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
63. Lemos P.A., Saia F., Hofma S.H., et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared with conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 43 (2004) 704-708
64. Popma J.J., Leon M.B., Moses J.W., et al. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 110 (2004) 3773-3780
65. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
66. Katritsis D.G., and Ioannidis J.P.A. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease. A meta-analysis. Circulation 111 (2005) 2906-2912
67. Henderson R.A., Pocock S.J., Clayton T.C., et al. Seven-year outcome in the RITA-2 trial. Coronary angioplasty versus medical therapy. J Am Coll Cardiol 42 (2003) 1167-1170
68. Al Suwaidi J., Holmes Jr. D.R., Salam A.M., Lennon R., and Berger P.B. Impact of coronary artery stents on mortality and nonfatal myocardial infarction. meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J 147 (2004) 815-822
69. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
70. Katritsis D.G., Karvouni E., and Ioannidis J.P. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 95 (2005) 640-643
71. Casscells W., Naghavi M., and Willerson J.T. Vulnerable atherosclerotic plaque. A multifocal disease. Circulation 107 (2003) 2072
72. Rioufol G., Finet G., Ginon I., et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome. a three-vessel intravascular ultrasound study. Circulation 106 (2002) 804-808
73. Schoenhagen P., Stone G.W., Nissen S.E., et al. Coronary plaque morphology and frequency of ulceration distant from culprit lesions in patients with unstable and stable presentation. Arterioscler Thromb Vasc Biol 23 (2003) 1895-1900